Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q1 2022 call → NOWe need to determine if management's forward account is substantially about counterparties' own growth/expansion, with the company already embedded, and the trajectory early and large. Key parts: - Pfizer launching Neglina (Somatrogon) in Germany, Japan, Canada, Australia. Milestones triggered. But is this about Pfizer's own scaling? Management mentions launches and milestones, but not detailed ramp of Pfizer's own activities. It's more about regulatory approvals and milestones. - Sema4 acquisition of GeneDx: This is about divesting GeneDx, not about counterparty growth driving OPKO's business. - BioReference: mentions commercial payer interactions (Aetna, UnitedHealthcare) preferred status, but that's about contracts, not about those payers' own expansion. Mentions Scarlet Health with Teladoc and MVP Healthcare - Teladoc is a telehealth provider, but management says "Scarlet is now offered by Teladoc Health as part of their new whole person health care experience." That is a partnership, but does management describe Teladoc's own scaling? Not really. It's just an agreement. - COVID testing: mentions schools, cruise lines, sports industry. But that's general, not specific counterparties' build-out. - The ModeX acquisition: that's about internal R&D, not counterparties. The question asks: does management explain where the company's business is going by narrating what its counterparties are themselves doing and scaling? The key is whether a substantial part of the forward account consists of reporting on the growth of specific customers/partners that the company already supplies, such that the company's volume is a consequence of those parties' trajectories. Looking at the transcript: - Pfizer launches: "Pfizer recently launched Neglina in the major markets of Germany and Japan as well as in Canada and Australia." That's about Pfizer's actions, but it's not about scaling up over time. It's just a launch event. Also, "Pfizer is continuing to work with the FDA to resolve any remaining issues" - that's about regulatory, not scaling. - The $85 million milestone is a one-time payment, not a ramp. - For BioReference, they mention "preferred status with Aetna" and "UnitedHealthcare" - but that's about contracts, not about those payers' own expansion. They don't describe Aetna or UnitedHealthcare building out networks or adding members.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.